Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Nanoparticles in Biotechnology, Drug Development and Drug Delivery


Published on

  • Be the first to comment

  • Be the first to like this

Nanoparticles in Biotechnology, Drug Development and Drug Delivery

  1. 1. Nanoparticles in Biotechnology, Drug Development and DrugDeliveryReport Details:Published:September 2012No. of Pages: 160Price: Single User License – US$4850•The global market for nanoparticles in biotechnology, drug development and drug delivery was valued at $17.5 billion in 2011 and should reach nearly $21.6 billion in 2012. Total market value is expected to reach $53.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 19.9%.•Drug delivery systems are expected to increase from $11.3 billion in 2012 to $30.9 billion in 2017, a CAGR of 22.2%.•Drug development and formulation should total nearly $9.4 billion in 2012 and nearly $20.5 billion in 2017, a CAGR of 16.9%.REPORT SCOPEINTRODUCTIONSTUDY GOALS AND OBJECTIVESThis study provides a comprehensive analysis of the market for nanoparticles in the life scienceson a global basis. Particular attention is given to drug development and formulation and thedevelopment of new drug delivery systems. Its aim is to provide a range of information, fromdetailed product analyses within health and wellness subsegments to overall industry trends inorder to quantify and qualify the market for drug products for treating various disease conditions inboth men and women. The applicability of specific types of nanoparticles for specific applicationsis discussed.Forecasts and trends are developed from a cross-reference of data points gleaned fromproprietary industry sources, company publications, industry benchmarking and other divergentdata sources to arrive at a cogent and coordinated forecast.REASONS FOR DOING THE STUDYFor companies with an effective strategy, market opportunities await. Importantly, the ability to
  2. 2. develop an effective strategy begins with knowing where opportunity exists and ends with a plan toeffectively execute in order to capture profit from opportunity.The nanoparticle drug/delivery market presents an increasingly significant part of the overallpharmaceutical product market worldwide. This study investigates the specific classes ofnanoparticles and the pharmaceutical products associated with them. Existing drug products andpotential drugs in the pipelines of the major pharmaceutical players in this market are reviewed.Growing health concerns in developing countries are expected to continue to contributesubstantially to market growth through the forecast period (2012 through 2017). This reportanalyzes emerging markets by technology category. Continued growth is expected in emerginggeographies driven by the health awareness of the growing middle class in emerging countriessuch as India, China, Brazil and Russia.This report seeks to address the critically important topics of analyzing a changing marketdynamic, emerging players and products, strategies for accessing emerging markets andawareness of specific disease prevalence and geographies thereof in order to allocate resourcesand make effective decisions.SCOPE OF REPORTCurrent and projected product forecasts during the forecast period of 2012 through 2017 arediscussed. New product launches will be discussed. Revenue figure for 2011 are in an actualfigures except where actual results have not been reported due to the timing of this report’srelease.The report includes analysis of leading and emerging drug products for each nanoparticle type.Profiles of manufacturers of leading products and their specific products are provided. This reportalso assesses companies poised to introduce products during the forecast period and discusseshow these introductions will change the face of the competitive environment. The competitiveenvironment is examined with a special focus on how new products will alter the quality of life ofpatients receiving nanoparticle-associated drugs.Market figures are based on revenues at the manufacturer level and are projected at 2011 dollarvalue. Inflation is not computed into the projection figures. Trends are assessed based onprojected sales for existing products, for new product introductions, expanded markets for existingproducts and other factors affecting the market.Included in this report are forecasts by product, product category and by company from 2010through 2017. The study is arranged to offer an overview of existing nanoparticle technology andof drug markets; it is accompanied by nanoproduct, company, geography, and mechanism ofaction, with forecasts broken down and covered by geographic region or country.
  3. 3. Patent and clinical trial information is reviewed for various candidate nanodrugs. The status ofapprovals of drugs in each segment by the FDA and regulatory agencies in other countries isreviewed.Figures are reported in U.S. dollars and in each case reflect currency fluctuations within theperformance of revenue change. Revenue figures do not account for variation in local currencies.All market share data presented is on a global basis unless specifically noted.INTENDED AUDIENCEThis report is an invaluable tool for business planners, acquisitions specialists, licensingstrategists, product managers, market research analysts, investors, investor consultants andanyone interested in the nanoparticle drug market, its products, its industry participants and itsfuture.The importance of identifying overall market trends, product opportunities, emerging geographies,merger and acquisition (M&A) opportunities and insights that provide guidance for sales growth ordefensive moves cannot be overstated for a variety of constituents, including:Established companies in the industry shall benefit from the contents, including corporate strategy,sales and marketing, business development and R&D.Emerging players in the segment must understand specific opportunities for out-licensingoriginating from the elements of differentiation of their product or technology as compared toleading, competitive and emerging products. As well, market forecasts can support investmentprovided a thorough and detailed substantiation is provided for the market forecast, as is found inthis study.Investment firms evaluating candidates for venture capital or hedged investments will gain insightsas to the opportunities and risks that are being encountered in the industry in a product- andcompany-specific analysis.Equity analysts are provided detailed forecasts for the next five years, substantiated byquantitative analysis that can support further analysis to product and company forecasts over theshort and long run.METHODOLOGY AND INFORMATION SOURCESIn-depth interviews were conducted with leading experts in the field who are executives incompanies, industry analysts, and leading individuals in the field.
  4. 4. The nanoparticle biomedical technology market is comprised of drug products for treatment of anassortment of specific diseases of both men and women. For completeness, the current andforecasted markets are comprised of the total market opportunity for each respective segment.Within each subsection there are detailed forecasts for each driving mechanism or relevant area ofgrowth.Information to prepare this report was obtained from participating and emerging companies in thenanoparticle area and from the National Institute of Kidney and Urologic Diseases InformationClearinghouse (NKUDIC), a service of Nat. Inst. of Diabetes and Digestive and Kidney Diseases(NIDDK), National Library of Medicine (NLM, NIH). Additional information was obtained from avariety of medical and technical journals in the various specialties of the nanoparticle applications.Other sources include: the New York Times, Wall Street Journal, Washington Post, othernewspapers, company documents and other websites. Population estimates are based on thosereported by the International database of the U.S. Census Bureau. Statistical data was obtainedfrom the World Health Organization (WHO), National Institute of Health (NIH) and WHOCollaborating Centre for Drug Statistics Methodology (Norway).Current and historical revenue figures for individual products have been sourced from companydisclosures that exist in the public domain or from government sources.ANALYST CREDENTIALSJackson Highsmith is a life sciences research consultant with more than 16 years of researchexperience. Jackson has been consulting with specialty pharmaceuticals and largepharmaceutical industry players since 2007. Prior to that, he worked at a large researchconsultancy where he focused on in-depth research; he also has worked at a large pharmaceuticalcompany in a wide range of medical therapeutics in early- and mid-stage drug development.Get your copy of this report @ points covered in Table of Contents of this report includeTable Of ContentsChapter- 1: Introduction - Complimentary 4Study Goals And ObjectivesReasons For Doing The StudyScope Of ReportIntended AudienceMethodology And Information SourcesAnalyst Credentials
  5. 5. Related Bcc ReportsBcc On-Line ServicesDisclaimerChapter- 2: Summary 2Table Summary : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals,Through 2017Figure Summary : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals, 2010-2017Chapter- 3: Overview 12Nanoparticle OverviewBrief History Of NanoparticlesNanoparticles In BiotechnologyNanoparticles In Drug DevelopmentNanoparticles In Drug Delivery SystemsNanoparticles In Diagnostic ImagingMajor Players In Nanoparticle Drug Delivery FieldChapter- 4: Global Market For Nanoparticles In Life Science 5Global Market For Nanoparticles In BiotechnologyGlobal Market For Nanoparticles In Drug DevelopmentGlobal Market For Nanoparticles In Drug Delivery SystemsGlobal Market For Nanoparticles In Diagnostic ImagingTable 9 : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals, Through 2017Chapter- 5: Nanoparticles Structure 6Adoption Of Nanoparticles In Applied MarketsChapter- 6: Nanoparticle Production 9Method Of Nanoparticle FormationSelf-Assembly ProductionMethods Of StabilizationMethods Of Drug IntroductionMethods Of Loading Biological Molecules Into NanoparticlesNanocrystal DrugsProblem With Large-Scale Nanoparticle ProductionChapter- 7: Nanoparticles In Biotechnology 7Research And DevelopmentStem Cell ResearchCellular Repair
  6. 6. In Vitro ImagingParamagnetic And Superparamagnetic NanoparticlesBiosensors And Quantum DotsTable 17 : Nanoparticles In Biotechnology ApplicationsChapter- 8: Nanoparticles In Drug Development And Formulation 12BioseparationsRapid Drug AnalysisRemoval Of Impurities And ToxinsUsing Nanoparticles To Incorporate Insoluble DrugsScreening/Profiling Drug CandidatesCombining Antibodies And Drugs Into NanoparticlesGold And Silver Nanoparticles In BiomedicineDna Nanoparticle Development Of Dna-Specific DrugsTable 19 : Nanoparticles In Drug Development ApplicationsChapter- 9: Nanoparticles In Drug Delivery Systems 39Nanoparticles In Drug Delivery ApplicationsDesigning A Nanoparticle Drug Delivery SystemNanoparticle Drug StabilitySize Homogeneity Of Nanoparticle PreparationsDrug Loading Of NanoparticlesDrug Release From NanoparticleExternal Triggers For Releasing Drug From NanoparticlesBinding/Incorporation Of Biomolecules To NanoparticlesNanoparticle ToxicityLarge-Scale ManufacturingMethods Of Administration Of Nanoparticle DrugsNanoparticle Drug Delivery System Currently AvailableRemoval Of Nanoparticles From The BodyChapter- 10: In Vitro And In Vivo Diagnostic Imaging 3In Vitro ImagingNanoparticles In Diagnostic ImagingChapter- 11: Biomedical Nanoparticle Products 21Current Fda-Approved Nanoparticle Drug ProductsMajor Players In Nanoparticle Drug Delivery SystemsCompany Pipelines For Nanoparticle Drug DeliveryDrivers Of Nanoparticle Products And MarketingLimiters Of Nanoparticle Product Development And Marketing
  7. 7. Chapter- 12: Global Market For Nanoparticle Drugs And Delivery Systems 3The Global MarketChapter- 13: Clinical Trials Of Nanoparticle Drugs And Drug Delivery Systems 6Table 43 : Clinical Trials For Nanoparticle Drugs And Drug Delivery SystemsTable 44 : Clinical Trials For Nanoparticle Drugs And Drug Delivery SystemsTable 45 : Clinical Trials For Nanoparticle Drugs And Drug Delivery SystemsChapter- 14: Patents, Licensing, Mergers And Acquisitions 11Nanoparticle PatentsU.S. Patents For Nanoparticles Drug DevelopmentU.S. Patents For Nanoparticle Drug DeliveryQuantum Dot PatentsTable 46 : Major Licensing, Collaborative Partnerships And Merger And Acquisition ActivitiesChapter- 15: Company Profiles 20Abraxis Biosciences, IncAbraxis Pharmaceutical ProductsAccess Pharma, Inc.Alnylam Pharmaceuticals, Inc.Amag Pharmaceuticals, Inc.Aphios CorporationAsklepios Biopharmaceutical, Inc.Astrazeneca Pharmaceuticals, PlcBind Biosciences, IncCerulean Pharma Inc.ConvatecDebiotech, S.A.Elan Pharmaceuticals, Inc.Flamel Technologies, IncGe Global ResearchMagforce Nanotechnologies AgMiv Therapeutics Inc.Nanocarrier Co., Ltd.Nano Interface Technology, IncNanosphere, Inc.Novartis International AgPharmasol CorporationSkyepharma, PlcStarpharma Holdings, LtdTalon Therapeutics, Inc.T2 Biosystems Inc.
  8. 8. List Of TablesSummary Table : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals,Through 2017Table 1 : Description Of Nanoparticles Used In Drug Delivery And Diagnostic ImagingTable 2 : Application Of Nanoparticles In BiotechnologyTable 3 : Application Of Nanoparticles In Drug DevelopmentTable 4 : Application Of Nanoparticles In Drug Delivery SystemsTable 5 : Nanoparticle Drug Delivery SystemsTable 6 : Nanoparticles Used For In Vivo Diagnostic ImagingTable 7 : Major Players In Nanoparticle Drug FieldTable 8 : Major Player Company Revenues For Nanoparticle Drugs, Through 2017Table 9 : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals, Through 2017Table 10 : Global Revenues Biotechnology Applications Of Nanoparticles, Through 2017Table 11 : Global Market For Nanoparticles In Drug Development And Formulation, Through 2017Table 12 : Global Revenues From Nanoparticles In Drug Delivery Systems, Through 2017Table 13 : Global Revenues From Nanoparticles In Diagnostic Imaging Systems, Through 2017Table 14 : Nanoparticle Structure And PropertiesTable 15 : Sample Of Drugs Delivered Through Liposome NanotechnologyTable 16 : Approved Nanocrystal DrugsTable 17 : Nanoparticles In Biotechnology ApplicationsTable 18 : Nanobiosensor Technology Under DevelopmentTable 19 : Nanoparticles In Drug Development ApplicationsTable 20 : Monoclonal Antibody (Mab) Drugs With Potential For Use In Nanoparticle DeliverySystemsTable 21 : Solid Lipid Nanoparticle-Reformatted DrugsTable 22 : Nanoparticles In Drug Delivery ApplicationsTable 23 : Standard Routes Of Drug AdministrationTable 24 : Nanoparticle Transdermal Patch ProductsTable 25 : Types Of Nanoparticles Supplied In Drug Delivery SystemsTable 26 : Nanocrystal Drugs Approved By The FdaTable 27 : Mechanisms For Removal Of Nanoparticles From The BodyTable 28 : Nanoparticle Contrast Media Used For In Vivo Diagnostic ImagingTable 29 : Current Fda-Approved Nanoparticle Drug Delivery SystemsTable 30 : Fda-Approved Drugs Specifically For Cancer TreatmentTable 31 : Fda-Approved Drugs For Central Nervous System DiseasesTable 32 : Major Players In Nanoparticle Drug Development And Formulation MarketTable 33 : Company Pipeline For Cardiovascular Nanoparticle DrugsTable 34 : Company Pipeline For Cns Disease Nanoparticle DrugsTable 35 : Company Pipeline For Gi Disease Nanoparticle DrugsTable 36 : Company Pipeline For Infectious Disease Nanoparticle Drugs
  9. 9. Table 37 : Company Pipeline For Cancer Nanoparticle DrugsTable 38 : Company Pipeline For Ophthalmic Nanoparticle DrugsTable 39 : Company Pipeline For Autoimmune Disease Nanoparticle DrugsTable 40 : Global Market For Nanoparticle Drugs And Diagnostic Imaging, Through 2017Table 41 : Global Market For Nanoparticle Drug Development And Formulation And Drug DeliverySystems, Through 2017Table 42 : Global Market For Diagnostic Imaging And In Vitro Imaging, Through 2017Table 43 : Clinical Trials For Nanoparticle Drugs And Drug Delivery SystemsTable 44 : Clinical Trials For Nanoparticle Drugs And Drug Delivery SystemsTable 45 : Clinical Trials For Nanoparticle Drugs And Drug Delivery SystemsTable 46 : Major Licensing, Collaborative Partnerships And Merger And Acquisition ActivitiesTable 47 : Global Percentage Share Of Patents Issued By Geography, From 2008 To 2011Table 48 : U.S. Patents For Nanoparticle Drug DevelopmentTable 49 : U.S. Patents For Nanoparticle Drug DeliveryTable 50 : U.S. Patents For Quantum Dot Technology Applied To Medical ApplicationsList Of FiguresSummary Figure : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals, 2010-2017Contact: for more information.